World Diabetic Macular Edema Pipeline Review 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2016" drug pipelines to their offering.

This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Diabetic Macular Edema Overview
  3. Therapeutics Development
  4. Pipeline Products for Diabetic Macular Edema - Overview
  5. Pipeline Products for Diabetic Macular Edema - Comparative Analysis
  6. Diabetic Macular Edema - Therapeutics under Development by Companies
  7. Diabetic Macular Edema - Therapeutics under Investigation by Universities/Institutes
  8. Diabetic Macular Edema Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Diabetic Macular Edema - Products under Development by Companies
  13. Diabetic Macular Edema - Products under Investigation by Universities/Institutes
  14. Diabetic Macular Edema - Companies Involved in Therapeutics Development (Partial List)
  • Aciont Inc.
  • ActiveSite Pharmaceuticals, Inc.
  • Adverum Biotechnologies, Inc.
  • Aerpio Therapeutics, Inc.
  • Allergan Plc
  • Ampio Pharmaceuticals, Inc.
  • Araim Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Boehringer Ingelheim GmbH
  • Chengdu Kanghong Pharmaceuticals

For more information about this drug pipelines visit http://www.researchandmarkets.com/research/b7vp8q/diabetic_macular

Related Topics: Cardiovascular Drugs, Optical, Endocrine and Metabolic Disorder Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716